Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study

Basit Öğe Kaydı
dc.contributor.authorOnsun, Nahide
dc.contributor.authorAkaslan, Tahsin Cagdas
dc.contributor.authorSallahoglu, Kadriye
dc.contributor.authorGulcan, Aliye Sevdem
dc.contributor.authorBulut, Huri
dc.contributor.authorYabaci, Aysegul
dc.date.accessioned2021-03-12T08:22:03Z
dc.date.available2021-03-12T08:22:03Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Psoriasis is a chronic inflammatory disease associated with obesity and metabolic syndrome. Adipokines are thought to be a link between psoriasis and obesity. Leptin, adiponectin, and omentin are bioactive adipokines thought to play a role in both metabolic comorbidities and inflammation. Anti-tumour necrosis factor alfa (anti-TNF-?) agents are effective for psoriasis treatment, although significant weight gain has been reported during anti-TNF-? therapy. The interleukin 12/23 (IL 12/23) inhibitor ustekinumab is also effective for psoriasis treatment. We compared the effects of three anti-TNF-? drugs and an IL-12/23 inhibitor on adipokines and weight gain during treatment. Patients and methods: This prospective study included 80 patients (37 women, 43 men) with moderate to severe plaque psoriasis whose age and weight were matched. The patients were divided into four equal groups: etanercept, infliximab, adalimumab, and ustekinumab treatment groups. Psoriasis Area Severity Index (PASI) score, body weight (muscle and fat compartments), and leptin, adiponectin, and omentin levels were evaluated at baseline and weeks 4, 12, 24, and 48 of treatment. Results: There were no differences between drug groups in terms of weight parameters or biochemical parameters at baseline. At the end of 48 weeks, there was significant weight gain in the adalimumab group. Patients who received infliximab showed significant weight gain by week 12, but in the following weeks they returned to their initial weight. Body weight reached a maximum level by week 12 in patients using etanercept, but they lost weight in the following weeks and finished the study below their initial weight. Patients using ustekinumab did not demonstrate significant weight change during the 48 weeks except at week 12. At the end of week 48, PASI75 (improvement in PASI ?75%) response rates were approximately 85% for the ustekinumab group, 80% for the adalimumab group, 75% for the infliximab group, and 50% for the etanercept group. Leptin, adiponectin, and omentin levels were higher in the ustekinumab group at all weeks except baseline. The lowest levels were observed in the etanercept group. The treatment response rate was also lower in the etanercept group. Limitations: We did not evaluate visfatin and resistin levels, insulin sensitivity, and cardiovascular risk that may be associated with weight gain and adipokine levels. Conclusions: Unlike TNF inhibitors, ustekinumab does not cause significant weight changes and it increases adipokine levels more than TNF inhibitors. Adipokine levels seem to be related to the treatment response.en_US
dc.identifier.citationOnsun, N., Akaslan, T. Ç., Sallahoglu, K., Gülcan, A. S., Bulut, H., & Yabacı, A. (2021). Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: A 48-week comparative study. The Journal of dermatological treatment, 1–16. Advance online publication. https://doi.org/10.1080/09546634.2021.1901845en_US
dc.identifier.doi10.1080/09546634.2021.1901845en_US
dc.identifier.endpage16en_US
dc.identifier.pmid33704001en_US
dc.identifier.scopus2-s2.0-85127205357en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1080/09546634.2021.1901845
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1563
dc.identifier.wosWOS:000772348300001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBulut, Huri
dc.language.isoenen_US
dc.publisherTaylor and Francisen_US
dc.relation.ispartofJournal of Dermatological Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdipokinesen_US
dc.subjectAdiponectinen_US
dc.subjectLeptinen_US
dc.subjectOmentinen_US
dc.subjectPsoriasisen_US
dc.subjectWeight Parametersen_US
dc.titleEffects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
32.pdf
Boyut:
562.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu